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Abstract
ATP2B2 encodes the PMCA2  Ca2+ pump that plays an important role in maintaining ion homeostasis in hair cells among 
others by extrusion of  Ca2+ from the stereocilia to the endolymph. Several mouse models have been described for this gene; 
mice heterozygous for loss-of-function defects display a rapidly progressive high-frequency hearing impairment. Up to now 
ATP2B2 has only been reported as a modifier, or in a digenic mechanism with CDH23 for hearing impairment in humans. 
Whole exome sequencing in hearing impaired index cases of Dutch and Polish origins revealed five novel heterozygous 
(predicted to be) loss-of-function variants of ATP2B2. Two variants, c.1963G>T (p.Glu655*) and c.955delG (p.Ala319fs), 
occurred de novo. Three variants c.397+1G>A (p.?), c.1998C>A (p.Cys666*), and c.2329C>T (p.Arg777*), were identified 
in families with an autosomal dominant inheritance pattern of hearing impairment. After normal newborn hearing screen-
ing, a rapidly progressive high-frequency hearing impairment was diagnosed at the age of about 3–6 years. Subjects had no 
balance complaints and vestibular testing did not yield abnormalities. There was no evidence for retrocochlear pathology 
or structural inner ear abnormalities. Although a digenic inheritance pattern of hearing impairment has been reported for 
heterozygous missense variants of ATP2B2 and CDH23, our findings indicate a monogenic cause of hearing impairment in 
cases with loss-of-function variants of ATP2B2.
Introduction
Hearing impairment (HI) is an important cause of social bur-
den worldwide (WHO 2008). The reported incidence in early 
childhood varies from 1 to 3/1000 (Wroblewska-Seniuk 
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et al. 2017). It is estimated that early onset sensorineural HI 
(SNHI) is hereditary in about 50% of the cases and in 20% 
of the cases nonsyndromic SNHI is inherited in an autoso-
mal dominant pattern (Smith et al. 2005). Until now, more 
than 60 loci and 37 genes have been identified for autoso-
mal dominant nonsyndromic SNHI (Hereditary Hearing 
loss Homepage). Still, for many subjects with congenital or 
childhood-onset HI, a genetic diagnosis cannot be provided 
(Zazo Seco et al. 2017). For several of the genes (recently) 
described to be associated with early onset HI, defects have 
so far been found in only a few or one single family. To 
confirm the association of such genes with HI, additional 
supportive data are required. Mouse models have contrib-
uted such evidence for several genes and have been of great 
significance by providing candidate genes for HI in humans 
(Brown et al. 2008; Friedman et al. 2007; Wesdorp et al. 
2018).
The plasma membrane  Ca2+ ATPase 2 (PMCA2), 
encoded by Atp2b2, has already been known for 2 decades 
to be essential for hearing and balance in mouse (e.g. the 
deafwaddler mouse) (Street et al. 1998). It is one of the 
two PMCAs with a tissue-specific expression; PMCA2 is 
mainly expressed in the inner ear, the cerebellum and the 
mammary gland. Alternative splicing of Atp2b2 transcripts 
results in several PMCA2 isoforms, e.g. PMCA2 w/a, or z/a 
[for review (Strehler and Zacharias 2001)]. Isoform PMCA2 
w/a is the major PMCA2 isoform in the organ of Corti and 
is encoded by a transcript with three alternatively spliced 
exons at the first alternative splice site, site A (Grati et al. 
2006; Hill et al. 2006). Given the structural and functional 
homology of the inner ear in mice, rat and human, PMCA2 
was anticipated to be critical for hearing in humans as well, 
and indications for that have already been reported. A hypo-
functional variant of PMCA2 (p.Val586Met) was found to 
aggravate HI in a family with a homozygous CDH23 vari-
ant (Schultz et al. 2005). Moreover, digenic inheritance of 
SNHI was suggested in an isolated case with heterozygous 
missense variants in both ATP2B2 and CDH23 (Ficarella 
et al. 2007). Furthermore, SNHI in cases with the 3p dele-
tion syndrome (MIM 613792) was suggested to be cor-
related with haploinsufficiency of ATP2B2 (McCullough 
et al. 2007). A heterozygous missense variant in ATP2B2 
has recently been associated with ataxia but without HI; the 
identified variant functionally affected a PMCA2 isoform 
that is expressed in the cerebellum but not prominently in 
the inner ear (Vicario et al. 2018). Finally, two de novo trun-
cating variants in ATP2B2 have been reported in a study on 
autism (Takata et al. 2018). These studies, however, do not 
provide evidence for a causative association of ATP2B2 with 
monogenic SNHI.
Here, we report four different heterozygous truncating 
variants and one canonical splice site variant in ATP2B2 
in families with nonsyndromic progressive SNHI. In two 
of the families, the variants are de novo. All variants affect 
exons, or their splice sites, that encode the ortholog of the 
rat PMCA2 w/a isoform. This isoform is highly abundant in 
stereocilia of outer hair cells (OHC) and to a lesser extent at 
the apical surface of inner hair cells (IHC) (Hill et al. 2006).
Materials and methods
Clinical examination
This study was approved by the medical ethics committee 
of the Radboud University Medical Center in Nijmegen, the 
Netherlands and was carried out according to the Decla-
ration of Helsinki. Written informed consent was obtained 
from all participants or their legal representatives. Medical 
history was taken from all participants, with special atten-
tion paid to (acquired) HI and vestibular symptoms. Affected 
individuals underwent general ear, nose and throat (ENT) 
examinations in the Radboud University Medical Center or 
findings of ENT examination were taken from their medical 
history. Pure tone audiometry (PTA) was performed accord-
ing to current standards in a sound-attenuating booth, where 
air conduction hearing thresholds for the frequencies from 
250 Hz to 8 kHz were measured. Bone conduction thresh-
olds were measured for the frequencies 500 Hz–8 kHz. 
The age- and gender-specific 95th percentile thresholds for 
individual hearing levels for each frequency were derived 
from the International Organisation for Standardization; ISO 
7029:2017. Individuals were considered affected when pure 
tone thresholds for at least three frequencies were below the 
95th percentile (P95) for the better hearing ear. The GEN-
DEAF guidelines for the description of audiological data 
were applied in this study (Mazzoli et al. 2003). GraphPad 
Prism 6.0 (GraphPad, San Diego, CA, USA) was used to 
calculate an age-related typical audiogram (ARTA), based 
on linear regression, for the ages of 10–70 years as described 
(Huygen et al. 2003). Speech perception was assessed in 
a sound-attenuating booth with standard monosyllabic 
consonant–vowel–consonant Dutch word lists (Bosman 
and Smoorenburg 1995). Otoacoustic emissions and click-
evoked brainstem-evoked response audiometric (BERA) 
measurements were performed according to current stand-
ards. In the Netherlands, the first step of newborn hearing 
screening is carried out by the detection of transient evoked 
otoacoustic emissions (TEOAE) (van der Ploeg et al. 2012). 
If applicable, results of newborn hearing screening were 
assessed by hetero-anamnesis of parents. Vestibular func-
tion was assessed by electronystagmography (ENG), caloric 
irrigation testing, rotary chair stimulation and video head 
impulse tests (vHIT), as described previously (Oonk et al. 
2015). Additionally, cervical and ocular vestibular-evoked 
myogenic potentials (cVEMP/oVEMP) were measured 
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to assess saccular and utricular function, respectively, as 
described (Papathanasiou et al. 2014; Vanspauwen et al. 
2017). When responses were seen at ≤ 100 dB hearing level 
in cVEMP testing, saccular function was considered as 
present, otherwise absent (Papathanasiou et al. 2014). For 
oVEMPs, this normal value is ≤ 140 dB force level (Vans-
pauwen et al. 2017).
Subjects V.2 of family W18-0139 and I.1 of family W17-
0883 were not able to participate in clinical evaluations, but 
retrospective data were analyzed. Subjects IV.3, IV.4 and V.1 
of family W18-0139 did not consent for the study.
Genetic analyses
DNA was extracted from peripheral blood samples accord-
ing to standard procedures. Exomes were enriched with the 
Agilent SureSelectXT Human AllExon v4 or v5 kit (Santa 
Clara, CA, USA) and sequencing was performed on an 
Illumina HiSeq4000 system by BGI Europe (Copenhagen, 
Denmark). Read alignment to the human reference genome 
(GrCH37/hg19) and variant calling was performed using 
BWA (Li and Durbin 2009) and GATK (Broad Institute, 
Cambridge, MA, USA) software, respectively. Variant anno-
tation was performed using a custom-designed in-house 
annotation and variant evaluation pipeline. First, whole 
exome sequence (WES) data were analyzed for variants in 
a panel of 142 genes known to be associated with nonsyn-
dromic HI and relatively common syndromic forms of HI 
(gene list version DG 2.5; Hereditary Hearing Loss Exome 
Panel Genome Diagnostics Nijmegen-Maastricht, see Online 
Resource Table S1) in a diagnostic setting. Variants in the 
142 deafness-associated genes were classified according to 
guidelines from the Association for Clinical Genetic Sci-
ence and the Dutch Society of Clinical Genetic Laboratory 
Specialists (Wallis et al. 2013). To address other recently 
published deafness genes, WES data of all subjects were 
reanalyzed with the most recent version of the gene panel, 
version DG 2.11, which consists of 159 deafness genes, see 
Online Resource Table S1. Variants of the complete exome 
were evaluated according to the criteria described in the sup-
plemental methods section (see Online Resource).
Mean 20x coverage of the enriched regions in WES 
ranged between 93.5 and 98.0%. Copy number variation 
(CNV) was addressed by depth of coverage analysis with 
CoNIFER as described (Krumm et al. 2012; Pfundt et al. 
2017). Segregation analysis of selected variants was car-
ried out by Sanger Sequencing, as described (Wesdorp et al. 
2018). Primer sequences are available upon request. Con-
firmation of parental identities in the cases with de novo 
variants was performed with the AmpFLSTR™ Identifiler™ 
kit, according to the manufacturer’s protocol (Applied Bio-
systems, Thermo Fisher Scientific MA, USA).
Sequencing of CDH23 for individuals I.1 and II.1 of 
family W17-0883 and III.3 of family W18-0139 was per-
formed by massive parallel ion semiconductor sequencing 
as described (Diekstra et al. 2015).
Results
Loss‑of‑function variants in ATP2B2 are associated 
with hearing impairment
An otherwise healthy subject of Dutch origin with child-
hood-onset, rapidly progressive nonsyndromic SNHI (fam-
ily W18-0138, III.1, Fig. 1) was referred to our out-patient 
clinic for etiologic consultation. First, GJB2 was screened 
in routine diagnostics, which revealed a heterozygous vari-
ant of uncertain significance c.647G>T (NM_004004; 
p.Arg216Ile) [DFNA3A, (MIM 601544); DFNB1, (MIM 
220290)]. This variant was not associated with autosomal 
dominant HI as it was inherited from the unaffected mother. 
In addition, no variant was identified in the second GJB2 
allele by Sanger sequencing. Therefore, defects in GJB2 
were not considered to underlie the HI in the presented case. 
Subsequently, WES was performed, which revealed neither 
other (likely) pathogenic variants in genes of the deafness 
gene panel (version DG 2.5), nor CNVs of these genes. 
Finally, analysis of the complete WES data (beyond the gene 
panel for deafness) was carried out. Truncating variants and 
variants of canonical splice sites were considered potentially 
deleterious. Furthermore, other potentially pathogenic vari-
ants that met the criteria as provided in the supplemental 
methods section were considered (See Online Resource). 
This analysis revealed a truncating variant in ATP2B2: 
c.955delG (NM_001001331.2, p.Ala319fs), which was nei-
ther present in our in-house database (~ 20,000 exomes) nor 
in gnomAD (version r2.02) (Lek et al. 2016). Importantly, 
the ATP2B2 variant was not found in the parents and as both 
parental identities were confirmed, the variant was consid-
ered to be de novo (Fig. 1). Several heterozygous missense 
and truncating defects of the mouse ortholog of ATP2B2 
were associated with early onset, progressive high-frequency 
HI (Bortolozzi et al. 2010; Carpinelli et al. 2013; Kozel et al. 
1998; McCullough and Tempel 2004; Spiden et al. 2008; 
Street et al. 1998; Takahashi and Kitamura 1999; Tsai et al. 
2006; Watson and Tempel 2013; Xu et al. 2011). Therefore, 
we regarded the ATP2B2 variant to be an excellent candidate 
cause of the HI in this subject.
To confirm the association of ATP2B2 defects with 
SNHI in humans, WES data of about 700 index cases were 
analyzed for truncating variants and variants in canonical 
splice sites in this gene. In 110 of these cases, a dominant 
inheritance pattern of HI was indicated by the referring 
clinician. Defects of known genes associated with HI were 
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previously excluded for these cases in routine diagnostics, 
as indicated in the methods section. Three cases were found 
to have nonsense variants in ATP2B2, and one case a vari-
ant in a canonical splice site (Table 1). All four cases had 
a reported onset of HI in the first decade (Table 2). Seg-
regation analysis of the ATP2B2 variants in the respective 
families demonstrated that the c.1963G>T variant in subject 
III.2 of family W17-4352 was de novo, as it was not detected 
in the parents (Fig. 1) while both parental identities were 
confirmed. In families W17-0883 and W18-0111, the identi-
fied ATP2B2 variants co-segregated with the HI in three and 
one affected family members, respectively. In family W18-
0139, the ATP2B2 variant was present in two participating 
family members with early onset HI (IV.2 and V2) but also 
in individual III.3 who reported a late onset of HI, at the age 
of 55 years.
Other variants that could potentially be causative for HI in 
the families were addressed (Online Resource Tables S2 and 
S3). For families W18-0138 and W17-4352, both a dominant 
and recessive inheritance patterns were addressed. 11 vari-
ants met the described criteria and their segregation in the 
respective families was determined (Online Resources Fig. 
S1 and Table S2). In families W18-0138 and W17-4352, 
identified variants with a potentially dominant effect were 
not de novo but derived from a normal hearing parent and, 
therefore, considered unlikely to be pathogenic. Variants 
Fig. 1  Pedigrees and segregation of ATP2B2 variants. VA1–
VA5, variants in ATP2B2, as listed in Table  1 and in this figure. 
Nomenclature of variants VA1–VA5 is according to transcript 
NM_001001331.2. The subject marked in grey (III.3, W18-0139) has 
late-onset hearing impairment, in contrast to all other affected indi-
viduals. Subjects IV.3, IV.4 and V.1 of family W18-0139 did not par-
ticipate in this study. Deceased individuals are considered affected or 
unaffected by hetero-anamnesis. Index cases are indicated by arrows. 
+, reference sequence
Table 1  ATP2B2 variants 
identified in this study
VA1–VA5, variants in ATP2B2, as shown in the pedigrees in Fig.  1. The indicated genomic posi-
tions are according to GRCh37/hg19. The cDNA and amino acid positions are based on transcript 
NM_001001331.2. None of the variants are present in gnomAD version r2.02 or in our in-house WES 
database of ~ 20.000 exomes
Family code Variant code Genome cDNA Protein Number of 
segrega-
tions
W18-0111 VA1 Chr3:10452301C>T c.397+1G>A p.? 1
W18-0138 VA2 Chr3:10426997delG c.955delG p.(Ala319fs) De novo
W17-4352 VA3 Chr3:10400548C>A c.1963G>T p.(Glu655*) De novo
W17-0883 VA4 Chr3:10400513G>T c.1998C>A p.(Cys666*) 3
W18-0139 VA5 Chr3:10391871G>A c.2329C>T p.(Arg777*) 2
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with a potentially recessive effect were only found in DNM1 
(family W17-4352), a gene that is associated with deafness 
in mouse (Boumil et al. 2010). However, the variant of one 
of the alleles was predicted to be synonymous and to have no 
effect on splicing. In the families with dominantly inherited 
HI, only one candidate variant, c.3226G>C (p.Asp1076His) 
in MYO6, co-segregated with the HI in family W18-0111.
Since digenic and modifier mechanisms have been 
described for the combination of CDH23 and ATP2B2 vari-
ants (Ficarella et al. 2007; Schultz et al. 2005), we evalu-
ated all rare variants in CDH23 in the index cases. CDH23 
was completely covered in WES by at least ten reads for 
all coding exons. Six rare variants, named VC1–VC6, were 
identified and segregation analysis was performed (Online 
Resource Table S3 and Fig. S1). Four variants (VC1–VC4) 
are missense variants predicted to have a deleterious effect 
by at least two of the employed pathogenicity prediction 
tools. VC2 and VC3 are located in cis on the paternal allele 
and are co-inherited with the ATP2B2 variant in family 
W18-0111. VC1 and VC4 co-occurred with the de novo 
variants in families W18-0138 and W17-4352, respectively. 
Therefore, no segregation analysis was carried out. For an 
intronic (VC5) and a synonymous (VC6) variant, no effects 
on splicing or protein function were predicted. Also, VC5 
does not co-segregate with the ATP2B2 variant (and HI) in 
family W17-0883. Sequencing of CDH23 was performed in 
individuals I.1 and II.1 (W17-0883) to identify other vari-
ants in this gene that might contribute the HI. This revealed 
only common variants. VC6 co-occurred with the ATP2B2 
variant in subjects IV.2 and V2 of family W18-0139, but 
not in individual III.3. The latter reported to have devel-
oped HI around the age of 55 years. Sequencing of CDH23 
in this individual revealed that he carries the VC1 variant 
heterozygously.
Characteristics of ATP2B2‑associated HI
None of the affected subjects or their parents reported expo-
sure to excessive noise, long-term usage of antibiotics, his-
tory of head trauma or meningitis. Subjects III.3 and IV.2 of 
family W18-0139 reported complaints of tinnitus. All four 
subjects who underwent newborn hearing screening passed 
the first screening (Table 2). HI in all except two participat-
ing affected subjects was bilateral, sensorineural, symmetric, 
and mild to profound. For individual IV.2 of family W18-
139, who repeatedly underwent ear surgery of the left ear, 
and I.1 of family W17-0883 who had a conductive HI on his 
left ear due to previous cholesteatoma surgery, only data of 
the right ears are depicted and included in further evalua-
tions. For the other subjects, mean air conduction threshold 
values are depicted in Fig. 2 and employed in further analy-
ses. Audiogram configurations were (steeply) downsloping 
(Fig. 2) and the age of onset was in the first decade with 
one exception (Table 2). Subject III.3 of family W18-0139 
reported an onset age of 55 years, but no audiometry was 
performed before the age of 64 years. His hearing is clearly 
below the P95 for presbyacusis for the higher frequencies. 
Other affected subjects (IV.3, IV.4 and V.1) in this family 
Table 2  Individual results of otoscopy, pure tone audiometry, newborn hearing screening, imaging, and speech discrimination tests
Age of onset is the reported age of onset in years. Age during study is the age at which subjects had clinical testing for this study
y years, PTA pure tone average, mean of 0.5, 1 and 2 kHz air conduction thresholds, R right, L left, SRT speech reception threshold, SRS speech 
recognition score, NT not tested, N normal, NA not applicable, cong. congenital
a Only right ear was assessed
b Latest audiogram, made at the age indicated in the fifth column. An exception is individual W18-0138 III.1, for whom the penultimate audio-
gram at the age of 22 was used because of cochlear implantation in her right ear at the age of 24 years
Family Subject Newborn 
screening
Age of onset (y) Age during 
study (y)
Otoscopic examination Imaging PTAb SRTb Maximum 
SRS (%)b
CT MRI R L R L R L
W18-0111 III.1 Pass 2–5 11 L myringosclerosis N 22 37 27 47 85 88
II.3 NT Cong 45 N 62 62 65 70 92 70
W18-0138 III.1 NT 3 24 N N N 105 82 95 57 50 69
W17-4352 III.2 Pass 2 6 N N 70 75 60 60 70 65
W17-0883 III.1 Pass 4 9 N 33 40 36 40 82 74
III.2 Pass 6 6 N 17 22 15 19 100 100
II.1 NT 2–5 32 N N 62 57 70 72 NT NT
I.1a NT 2–5 67 NT 103a NA NT NA NT NA
W18-0139 V.2 NT 4 17 NT 23 22 10 10 95 100
IV.2a NT 5 48 Na N N 60 NA 67 NA 93 NA
III.3 NT 55 68 N 13 20 13 21 95 95
66 Human Genetics (2019) 138:61–72
1 3
did not participate in the clinical and genetic evaluations, but 
on hetero-anamnesis they had an early childhood onset of 
HI. Subject III.3 reported that his father, paternal aunts and 
grandmother had HI early in life and that they were wearing 
hearing aids.
Speech reception thresholds in general were lower than 
or comparable to pure tone average thresholds (0.5–2 kHz), 
(a)
(b)
Fig. 2  Audiograms of individuals with heterozygous deleterious 
ATP2B2 variants. a Air conduction thresholds of all participating 
individuals with a deleterious ATPB2B2 variant are depicted. For 
subjects I.1 of family W17-0883 and IV.2 of family W18-0139, only 
data of their right ears are displayed. For all other subjects, average of 
left and right ear thresholds is shown. The P95 values are matched to 
the individuals’ sex and age at first audiometry, according to the ISO 
7029:2017 standard. The lowest age for which the ISO 7029:2017 can 
be applied is 18 years. y, age in years. b Age-related typical audio-
gram (ARTA) representing cross-sectional linear regression analysis 
of last visit audiograms of all subjects with a deleterious ATP2B2 
variant (N = 11). The dashed line represents the average air conduc-
tion thresholds at the age of 5
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indicating the absence of retrocochlear pathology. This was 
confirmed by BERA measurements in four subjects (Online 
Resource Table S4, data not shown).
An ARTA was calculated to provide insight in the pro-
gression of the HI per decade (Fig. 2b). The average annual 
threshold deterioration (ATD) for the ages 10–70 was 0.5 
dB/year for the low frequencies (250–500Hz), 1.1 db/y for 
middle frequencies (1–2 kHz) and 0.7 dB/year for the high 
frequencies (4–8 kHz). Under the age of 10 years, audio-
grams tend to be less reliable due to more prevalent otitis 
media with effusion or less co-operation or cognitive capa-
bilities of the young subjects. To give insight in the HI at this 
age, we calculated the average thresholds of all subjects with 
a hearing test at about 5 years of age (Fig. 2b, dashed line).
Five subjects underwent computed tomography (CT) 
and/or magnetic resonance imaging (MRI) of the bilateral 
temporal bones/cochlea and cerebellopontine angle, which 
revealed normal inner and middle ear anatomy, except for 
the left ear of subject IV.2 of family W18-0139 for reasons 
already indicated (Table 2).
Results of vestibular testing
Vestibular history was obtained from all subjects and exten-
sive vestibular testing of at least one affected subject per 
family (except for family W17-4352) revealed only minor 
vestibular abnormalities (see Online Resource Table S4). 
Two subjects reported vestibular complaints; one was diag-
nosed with benign paroxysmal position vertigo (BPPV) and 
the second had complaints due to a perilymph leakage at 
cholesteatoma surgery. Saccular function could not be meas-
ured in subjects III.1 of family W18-0138 (bilaterally), III.1 
(left ear) of W18-0111, and IV.2 of W18-0139 (left ear), 
whereas utricular function was not measurable in III.1 of 
family W18-0138. Maximum stimulus levels were reached 
in all these subjects.
Discussion
In this study, five families were presented, in which four 
mono-allelic truncating variants and one canonical splice 
site variant in ATP2B2 co-segregated with early onset pro-
gressive nonsyndromic SNHI and with late-onset SNHI 
in one subject. All five variants affected the (predicted) 
ortholog of the w/a isoform of PMCA2, which is the pre-
dominant  Ca2+ATPase in rodent hair cells and specifically 
localizes to stereocilia (Grati et al. 2006; Hill et al. 2006). In 
man, transcripts encoding the w/a isoform of PMCA2 have 
so far not been identified but the w splicing pattern has been 
shown (ENSEMBL, UCSC genome browser). See Online 
Resource Fig. S2 for a schematic representation of the dif-
ferent isoforms and positions of the variants. The truncating 
variants can be predicted to have a loss-of-function effect. 
This might also be the case for the splice site variant by 
inducing skipping of exon 3, retention of intron 3 or the use 
of an alternative exonic or intronic splice site. Skipping of 
exon 3 (198 nucleotides) is predicted to result in the deple-
tion of 66 amino acids from the N-terminal part of the pro-
tein, including the first transmembrane region (See Online 
Resource Fig. S3 for splice prediction). Two of the truncat-
ing variants occurred de novo, which supports pathogenicity 
of the variants. A causal association with disease is further 
strengthened by a pLI score of 1.00 reported for ATP2B2. 
This score is an indication of extreme loss of function intol-
erance of ATP2B2 (Lek et al. 2016). The DOMINO vari-
ant effect prediction tool, predicts ATP2B2 to be very likely 
associated with a dominantly inherited disorder (Quinodoz 
et al. 2017) which is in agreement with the inheritance pat-
tern of HI in the described families.
As digenic inheritance of HI was proposed for mono-
allelic missense variants in ATP2B2 and CDH23 (Ficarella 
et al. 2007), we addressed this type of inheritance in the 
families in our study. Although rare CDH23 variants co-
occurred with ATP2B2 variants in all five index cases, our 
findings indicate that mono-allelic loss-of-function variants 
of ATP2B2 are the underlying cause of HI. First, the CDH23 
variant VC5 in individuals III.1 and III.2 of family W17-
0883 is intronic and predicted not to affect splicing. Fur-
thermore, this variant was not found in the affected family 
members I.1 and II.1, who also did not carry any other rare 
CDH23 variants in the coding sequences or flanking intronic 
regions. Second, the synonymous CDH23 variant VC6 in 
family W18-0139 is predicted not to affect the existing splice 
sites nor to introduce such sites. Although this variant did 
co-segregate with early onset HI in the family, subject III.3 
with late-onset HI carried a different CDH23 variant, namely 
missense variant VC1 that is also seen in the index case of 
family W18-0138. Third, none of the variants has been clas-
sified as (likely) pathogenic in Clinvar (VC1–VC3, (likely) 
benign; VC4, uncertain significance; VC6, conflicting, UV1/
UV2/UV3) and all but one (VC4) occur relatively frequently 
in gnomAD. Only variants in deep intronic regions or pro-
moter regions were not addressed and can, therefore, not be 
excluded. CNVs of CDH23 can be excluded for the index 
cases only. Finally, the affected individual in the family 
reported by Ficarella et al. was pre-screened only for muta-
tions in GJB6, MYO6, CDH23, and the most common muta-
tions in GJB2 (Ficarella et al. 2007). As many of the known 
genes associated with recessive HI were not tested, several 
of which are commonly involved (e.g. MYO15A), defects 
in other deafness genes cannot be excluded in the reported 
case. We cannot exclude a modifying effect of the CDH23 
variants on HI in the affected subjects in our study, as has 
been reported for mouse mutants of Atp2b2 (McCullough 
and Tempel 2004).
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As indicated by the pLI score of 1.00, loss-of-func-
tion variants in ATP2B2 are rare. In gnomAD, eight such 
variants are reported heterozygously, representing 26 
alleles. Three of these variants, representing 21 alleles, 
affect canonical splice sites of the alternatively spliced 
exons 7–9 at site A and all three are in frame (see Online 
Resource Fig. S2). One of these three variants, c.1001-
1G>A (NM_001001331.2), was identified in 19 non-
Finnish Europeans and is predicted to result in the loss 
of the splice acceptor site of exon 9. This loss potentially 
results in skipping of this exon and thereby to a shift from 
splicing pattern w to y at site A (Online Resource Fig. S2). 
Alternative splicing at site A determines apical targeting 
of the encoded PMCA2 in hair cells. When alternative 
splicing at site A resulted in insertion of at least 31 amino 
acids, the encoded PMCA2 exclusively targeted to the hair 
bundle (Grati et al. 2006). As exons 7, 8, and 9 encode 
11, 20, and 14 amino acids, respectively, skipping of exon 
9 results in 31 amino acids encoded at site A (pattern y) 
and exclusively apical targeting of the protein (Grati et al. 
2006). This suggests that the c.1001-1G>A might have no 
or a milder phenotypic effect compared to ATP2B2 vari-
ants identified in the present study.
The other two canonical splice site variants in gnomAD, 
each representing a single allele, are predicted to result in the 
loss of the splice donor site of exon 7 and the splice acceptor 
site of exon 8, respectively. Skipping of exon 7 would lead 
to a PMCA2 protein with 34 amino acids encoded by exons 
inserted at site A and thus apical targeting according to Grati 
et al. (Grati et al. 2006). Skipping of exon 8 would result in 
a PMCA2 protein with both apical and basolateral distribu-
tion in hair cells (Grati et al. 2006). In conclusion, 21 of 26 
loss-of-function alleles reported in gnomAD might well lead 
to no or a mild phenotype.
Two de novo truncating variants in ATP2B2 have 
been identified in a study on autism spectrum disorders 
(ASD), which is a complex disorder (Takata et al. 2018). 
These variants, c.2268C>A (p. Cys756*) and c.3191G>G 
(p.Trp1064*) according to transcript NM_001001331.2, 
affect exons 15 and 20 of the transcript, respectively (see 
Online Resource Fig. S2). Therefore, these variants are 
predicted to affect all known PMCA2 isoforms and to 
lead to nonsense-mediated decay. Based on our findings, 
the de novo ATP2B2 variants identified in the ASD cases 
are expected to cause HI but this was not reported by the 
authors. The age of the subjects was not specified but indi-
cated to be more than 2 years. This suggests that these sub-
jects might not yet have developed HI. Alternatively, if they 
are toddlers, the HI may have mimicked or contributed to 
symptoms of ASD due to communication problems as has 
been reported previously (Worley et al. 2011). The subjects 
in our study did not display signs of ASD and this condition 
was neither indicated by themselves nor by their parents.
The type of mutations and their distribution in the gene 
suggest haploinsufficiency as disease mechanism. 4 of 5 pre-
sented ATP2B2 variants potentially lead to nonsense-medi-
ated decay (NMD). A haploinsufficiency mechanism is fur-
ther supported by the findings of McCullough et al. (2007) 
who demonstrated that SNHI in cases with the 3p-syndrome 
is associated with loss of ATP2B2 (McCullough et  al. 
2007). They reported a high-frequency HI with a steeply 
downsloping audiogram configuration, similar to that in the 
cases in our study. Malmgren et al. suggested that deletion 
of ATP2B2 is not sufficient to cause HI (Malmgren et al. 
2007). However, the HI in the cases they reported is not 
sufficiently characterized to support SNHI in all them. For 
example, HI of one of the included subjects was indicated 
to be conductive in the original publication (Angeloni et al. 
1999; Malmgren et al. 2007; McCullough et al. 2007).
WES data of index cases were analyzed for other variants 
in known mouse and/or human deafness genes that could 
potentially be causative for HI. This revealed only one can-
didate variant, c.3226G>C (p.Asp1076His) in MYO6, that 
co-segregated with the HI in family W18-0111. Although a 
phenotypic effect of this variant cannot be excluded, MYO6 
variants with a dominant effect are known to be associated 
with progressive HI with a different audiogram configura-
tion and in the majority of cases an onset after childhood 
(Miyagawa et al. 2015; Oonk et al. 2013; Sampaio-Silva 
et al. 2018; Topsakal et al. 2010). Therefore, the identified 
variant is unlikely to fully explain the HI in family W18-
0111. Also, the HI in family W18-0111 is comparable to 
that in the other families reported in this study.
13 mouse mutants (deafwaddler) have been described for 
Atp2b2, 12 of which have been described to display congeni-
tal severe-to-profound HI accompanied by a severe vestibu-
lar/ataxic phenotype when the mutation is in the homozy-
gous state. The mutations in all 12 affect the w/a isoform of 
PMCA2. Mice with loss of function Atp2b2 mutations in 
the heterozogous state display a rapidly progressive early 
onset HI (before the age of 3–5 weeks) with high-frequency 
hearing being most severely affected (Carpinelli et al. 2013; 
McCullough and Tempel 2004; Noben-Trauth et al. 1997; 
Watson and Tempel 2013). The type of HI in these mice is 
highly similar to that in the presented affected subjects.
Based on the findings in the presented families, it can-
not be determined whether hearing of the affected subjects 
was abnormal at birth, as all four subjects who underwent 
newborn hearing screening passed the first test. The TEOAE 
devices employed in the screening are calibrated to detect 
thresholds of 35 dB HL or more, for the frequencies between 
1 and 4 kHz (van der Ploeg et al. 2012). This means that in 
case the tested newborns with ATP2B2 defects had elevated 
thresholds, these were below 35 dB HL for the tested fre-
quencies. Alternatively, only the thresholds for higher fre-
quencies (> 4 kHz) surpassed 35dB, which might have well 
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been the case based on audiogram configuration (Fig. 2b) 
and the findings in mouse models. Delayed speech devel-
opment and difficulties at school were the reasons for the 
parents to have their children’s hearing tested leading to a 
diagnosis of HI around the age of 2–5 years.
One individual (W18-0139, III.3, Fig. 1) in our study dis-
played HI with a late onset rather than an early onset. This 
suggests the existence of modifying (genetic) factors. For 
mouse, it has been described that small (15%) increases in 
PMCA2 activity can account for large differences in hear-
ing phenotype (McCullough and Tempel 2004). Therefore, 
it is tempting to speculate that the late onset of HI in this 
case might be due to a relatively high inner ear expression 
of the second ATP2B2 copy. As subject II.3 was indicated to 
be severely hearing impaired at the age of 30 years, mosaic 
presence of the ATP2B2 variant in subject III.3 seems 
unlikely to explain the late onset of his HI. However, as HI is 
genetically highly heterogeneous the deceased family mem-
bers I.2, II.1, II.2 and II.3 may have had HI with a different 
genetic aetiology. Identification of additional families with 
deletions or truncating variants of ATP2B2 will shed light 
on the variability of onset age of ATP2B2-associated HI.
In hair cells and endolymph,  Ca2+ is important for main-
taining the endocochlear potential, contributes to the mecha-
notransduction (MET) current, affects MET channel activ-
ity, tip-link structure, and, although under debate now, it is 
thought to play a role in the process of fast adaptation [for 
review see (Bortolozzi and Mammano 2018; Cali et al. 2017; 
Qiu and Muller 2018)]. PMCA2 is the  Ca2+ pump in OHC 
stereocilia and, therefore, important for  Ca2+ homeostasis 
in these structures. As has been demonstrated for several 
of the Atp2b2 mutant mice, HI and OHC dysfunctions pre-
cede hair cell degeneration and  Ca2+ cytotoxicity has been 
hypothesized to underlie the latter (Bortolozzi et al. 2010; 
Konrad-Martin et al. 2001; Spiden et al. 2008). Degeneration 
of both OHCs and IHCs was demonstrated to be most severe 
at the cochlear base in heterozygous as well as homozy-
gous Atp2b2 mutant mice (Bortolozzi et al. 2010; Spiden 
et al. 2008). This is in agreement with high-frequency hear-
ing being most severely affected in the presented families. 
Analogous to what has been described in mice with a het-
erozygous Atp2b2 mutation, degeneration of OHCs, IHCs 
and supporting cells is likely to cause the progression of HI 
to severe-to-profound in humans.
PMCA2 is also expressed in the stereocilia of ves-
tibular hair cells (Grati et al. 2006; Street et al. 1998). 
A vestibular phenotype was only seen in homozygous or 
compound heterozygous and not in heterozygous Atp2b2 
mutant mouse models (Bortolozzi et al. 2010; Carpinelli 
et al. 2013; Kozel et al. 1998; McCullough and Tempel 
2004; Spiden et al. 2008; Street et al. 1998; Sun et al. 
2008; Watson and Tempel 2013). This is histologically 
supported by studies of Takahashi and Kitamura on the 
“wri” mouse model; in wri/wri homozygotes, severe 
degeneration is seen in both the cochlea and saccule within 
3 months. In heterozygotes, degeneration was only seen 
in the cochlea (Takahashi and Kitamura 1999). Vestib-
ular complaints were found in only two patients in this 
study, but can be attributed to other factors than defects in 
ATP2B2 (Online Resource Table S4). Oculomotor, vHIT, 
caloric and rotational chair testing yielded no abnormali-
ties, as expected from previous studies in mouse models. 
In four subjects, we could not determine whether saccular 
or utricular function was present. First, we measured until 
100dB HL (cVEMP) and 140 dB FL (oVEMP), according 
to protocol. Higher stimulus levels are too uncomfortable 
for subjects. The contralateral measurements were close to 
maximum stimulus levels in subjects III.1 of family W18-
0111 and IV.2 of W18-0139. It is, therefore, possible that 
ipsilateral levels could have been measured with stimuli 
just above the maximum stimulus levels. Second, in about 
half of all patients who underwent vestibular examination 
in our clinic prior to cochlear implantation, it was impos-
sible to measure c- and oVEMPs (Beynon, unpublished 
data). This relates to subject III.1 of W18-0138, who was 
the only subject with a cochlear implant. Based on the 
present findings, we concluded that heterozygous loss-of 
function variants in ATP2B2 are unlikely to be associated 
with vestibular dysfunction.
In conclusion, we presented heterozygous ATP2B2 
defects to be associated with dominantly inherited non-
syndromic SNHI. All but one subject displayed a rapidly 
progressive high-frequency HI with a congenital or early 
childhood onset. Four and possibly all five identified vari-
ants have a truncating effect. As amino acid substitutions 
in mouse PMCA2 can lead to loss of function (e.g. Bor-
tolozzi et al. 2010; Spiden et al. 2008), missense variants 
in ATP2B2 are to be expected as a cause of HI in humans 
as well. Variants resulting in reduced PMCA2 function 
might lead to recessive HI, analogous to the deafwaddler 
(dfw) allele (McCullough and Tempel 2004).
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